Company Ticker News March 15, 2022Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results 0 0 Share
Company Ticker News February 28, 2022Frequency Therapeutics to Participate in Upcoming March 2022 Investor Conferences 0 0 Share
Company Ticker News January 4, 2022Frequency Therapeutics to Present 2022 Business and Pipeline Overview at the 40th Annual J.P. Morgan Healthcare Conference 0 0 Share
Company Ticker News November 15, 2021Frequency Therapeutics, Inc. (FREQ) Reports Q3 Loss, Lags Revenue Estimates 0 0 Share
Company Ticker News November 15, 2021Frequency Therapeutics Provides Business Updates and Third Quarter 2021 Financial Results 0 0 Share
Company Ticker News November 9, 2021Frequency Therapeutics redesigns study after disappointing Phase 2 results, debuts new hearing loss and MS drugs 0 0 Share
Press Release November 9, 2021Frequency Therapeutics Holds Virtual R&D Event Highlighting Clinical Advancement of FX-322, a New Potential Restorative Treatment for Hearing Loss and In Vivo Data for Its Remyelination Program in Multiple Sclerosis 0 0 Share
Company Ticker News November 8, 2021Analysts Estimate Frequency Therapeutics, Inc. (FREQ) to Report a Decline in Earnings: What to Look Out for 0 0 Share
Press Release October 27, 2021Frequency Therapeutics Virtual R&D Event to Detail FX-322 Clinical Advances, a New Program for Hearing Restoration and In Vivo Data from its MS Remyelination Program 0 0 Share
Company Ticker News October 21, 2021Frequency Therapeutics Announces First Subject Dosed in FX-322 Phase 2b Acquired Sensorineural Hearing Loss (SNHL) Study and FDA Agreement on Speech Perception as Primary Endpoint 0 0 Share
